Comparison of remimazolam total intravenous anesthesia versus sevoflurane inhalational anesthesia on emergence agitation in patients undergoing laparoscopic surgery for gastric or colorectal cancer: study protocol for a randomized controlled trial

Imagine you are waking up from a deep, dreamless sleep after a long surgery. For most people, this is a smooth transition from "out cold" to "wide awake." But for some, the journey back to consciousness is a bumpy, chaotic ride. Instead of gently opening their eyes, they might suddenly become confused, restless, or even aggressive, thrashing around and trying to pull out their tubes. In the medical world, this is called emergence agitation. It's like a car engine that revs way too high the moment you turn the key, instead of idling smoothly. This happens often after major surgeries, especially those involving the stomach or intestines done with tiny cameras (laparoscopic surgery), and it can be dangerous for the patient and stressful for the medical team.

To keep patients asleep during these operations, doctors use "anesthesia," which is essentially a chemical sleep. There are two main ways to deliver this sleep: inhalational anesthesia, where the patient breathes in a sweet-smelling gas (like sevoflurane) through a mask or tube, and total intravenous anesthesia (TIVA), where the patient gets a continuous drip of liquid drugs directly into their vein. Think of the gas as a fog that fills the room, and the IV drip as a precise stream of water. While both work, doctors have noticed that the "fog" sometimes seems to make the wake-up process more jumpy and agitated than the "stream." Now, a new, ultra-fast-acting liquid drug called remimazolam has entered the scene. It's like a super-efficient, short-lived sleep potion that might offer the best of both worlds: the smoothness of an IV drip without the jitters of the gas.

This paper is a study protocol, which is essentially a detailed recipe and game plan for a scientific experiment. The researchers at Jianyang People's Hospital in China are setting out to test a specific hypothesis: Will using the new liquid drug (remimazolam) result in fewer cases of that chaotic "bumpy wake-up" compared to the traditional gas (sevoflurane) in patients undergoing surgery for stomach or colon cancer?

The study is designed as a randomized controlled trial, which is the gold standard for testing medical ideas. Imagine a coin flip: 108 adult patients scheduled for these specific surgeries will be randomly assigned to one of two groups. One group will receive the new Remimazolam-based Total Intravenous Anesthesia (RTIVA), where they get a continuous drip of the drug mixed with a painkiller. The other group will receive the standard Sevoflurane-based Inhalational Anesthesia (SINH), breathing in the gas mixed with the same painkiller. Everything else about their care—how they are monitored, how their pain is managed, and how they are woken up—will be exactly the same to ensure a fair comparison.

The main thing the researchers are looking for is the incidence of emergence agitation. They will watch the patients closely in the recovery room (PACU) and use a special scoring system called the Ricker Sedation-Agitation Scale (RSAS) to see if patients are calm or if they are acting out (scoring a 5 or higher means agitation). If the new drug works, the RTIVA group should have significantly fewer patients acting up compared to the gas group.

But the researchers aren't just looking at the wake-up; they are also checking the whole journey. They will measure how long it takes for patients to wake up, how long they stay in the recovery room, and how they feel the next day using a "Quality of Recovery" score. They are even taking blood samples to check for signs of inflammation (specifically TNF-α and IL-6), wondering if the type of anesthesia changes how the body reacts to the surgery itself. They are also keeping a close eye on safety, watching for side effects like low blood pressure, slow heartbeats, or confusion.

It is important to note that this paper is a plan, not a report of finished results. The study is scheduled to run from March 2025 to October 2026. The authors are suggesting that remimazolam might be the better choice because it offers stable blood pressure and a quick, smooth recovery, but they haven't proven it yet. They are setting up this experiment to find out if the new drug can truly reduce the chaos of waking up for these cancer patients. If the results are positive, it could change how anesthesiologists manage these complex surgeries, potentially making the recovery room a much calmer place for everyone involved.